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Abstract
Vitamin D has been reported to influence physiological systems that extend far beyond its established functions in calcium 
and bone homeostasis. Prominent amongst these are the potent immunomodulatory effects of the active form of vitamin D, 
1,25-dihydroxyvitamin D3 (1,25-(OH)2D3). The nuclear vitamin D receptor (VDR) for 1,25-(OH)2D3 is expressed by many 
cells within the immune system and resulting effects include modulation of T cell phenotype to suppress pro-inflammatory 
Th1 and Th17 CD4+ T cells and promote tolerogenic regulatory T cells. In addition, antigen-presenting cells have been 
shown to express the enzyme 1α-hydroxylase that converts precursor 25-hydroxyvitamin D3 (25-OHD3) to 1,25-(OH)2D3, 
so that immune microenvironments are able to both activate and respond to vitamin D. As a consequence of this local, 
intracrine, system, immune responses may vary according to the availability of 25-OHD3, and vitamin D deficiency has 
been linked to various autoimmune disorders including rheumatoid arthritis (RA). The aim of this review is to explore the 
immune activities of vitamin D that impact autoimmune disease, with specific reference to RA. As well as outlining the 
mechanisms linking vitamin D with autoimmune disease, the review will also describe the different studies that have linked 
vitamin D status to RA, and the current supplementation studies that have explored the potential benefits of vitamin D for 
prevention or treatment of RA. The overall aim of the review is to provide a fresh perspective on the potential role of vitamin 
D in RA pathogenesis and treatment.
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Introduction
Vitamin D is a secosteroid which can be obtained from the 
diet (in particular from oily fish, eggs, dairy products and 
fortified foods). However, in humans, the majority of vita-
min D is synthesised in the skin from the precursor molecule 
7-dehydrocholesterol, which undergoes a series of UV light-
mediated modifications to generate parental vitamin D3 [1]. 
Vitamin D was first recognised for its role in bone miner-
alisation and calcium regulation, with vitamin D deficiency 
associated with the bone disease rickets [2]. More recently, 
vitamin D has been reported to exert many extra-skeletal 
effects [3] with association studies linking vitamin D status 
to a broad range of human health issues. Prominent amongst 
these is the proposed role of vitamin D in the pathophysi-
ology of autoimmune disease, including insulin-dependent 
type 1 diabetes mellitus (T1D) [4], autoimmune thyroid dis-
ease [5, 6], multiple sclerosis (MS), inflammatory bowel dis-
ease (IBD) [7], systemic lupus erythematosus (SLE) [8] and 
rheumatoid arthritis (RA) [9]. The underlying mechanisms 
by which vitamin D impacts autoimmune disease remain 
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elusive, and it is still not clear whether vitamin D deficiency 
contributes to autoimmune disease pathogenesis or whether 
it is marker of disease progression and severity. In this arti-
cle, we address these issues with specific reference to the 
role of vitamin D in RA. We discuss the potential clinical 
significance, and the mechanisms of action of vitamin D in 
RA, and suggest areas where future research is needed.
Vitamin D in Health
Humans obtain vitamin D in two forms; vitamin D2 (ergo-
calciferol, derived from plant ergosterols) and vitamin D3 
(cholecalciferol), which differ in the number/location of dou-
ble carbon–carbon bonds. Vitamin D2 has only two C=C 
bonds, whilst vitamin D3 has three, affording D2 a lower 
affinity for vitamin D-binding protein (DBP), increasing 
clearance and reduced bioavailability; thus, vitamin D3 is 
the main form of vitamin D used by humans. Generation of 
active, hormonal, vitamin D3 involves a series of non-enzy-
matic and enzymatic processes. Firstly, 7-dehydrocholesterol 
is converted to vitamin D3 when exposed to UVB light in 
the dermis. Vitamin D3 is then converted to 25-hydroxy-
cholecalciferol (25-OHD3) by the enzyme 25-hydroxylase 
(CYP2R1) located predominantly in the liver [10]. The final 
step in generating active 1,25-dihydroxycholecalciferol 
(1,25-(OH)2D3) is mediated by the enzyme 25-hydroxyvi-
tamin D-1α-hydroxylase (CYP27B1), which is abundant in 
the proximal tubule cells of the kidney [11]. This step is 
responsible for the majority of circulating 1,25-(OH)2D3, 
but CYP27B1 is also expressed by a variety of non-renal 
tissues [12], including several immune cell subsets [13–15], 
suggesting that these cells also have significant capacity to 
generate 1,25-(OH)2D3, with this process being instrumental 
in various autocrine and paracrine cell responses to vita-
min D [16, 17]. Moreover, whilst renal CYP27B1 is tightly 
regulated by parathyroid hormone, fibroblast growth factor 
23 and 1,25-(OH)2D3 itself, extra-renal CYP27B1 does not 
appear to be subject to the same regulatory constraints [18, 
19]. Instead extra-renal synthesis of 1,25-(OH)2D3 appears 
to be more dependent on the availability of 25-OHD3. In 
view of the fact that 25-OHD3 is the main determinant 
of serum vitamin D status, it is highly likely that extra-
renal synthesis of 1,25-(OH)2D3 will therefore be strongly 
influenced by vitamin D deficiency/sufficiency. The avail-
ability of 25-OHD3 is also affected by circulating serum 
carrier proteins for vitamin D: Vitamin D-Binding Protein 
(VBP), and to a lesser extent albumin [20, 21]. Levels of 
1,25-(OH)2D3 in either renal or extra-renal settings are 
also influenced by catabolism of 1,25-(OH)2D3 to inactive 
metabolites which is primarily controlled by the enzyme 
24-hydroxylase (CYP24A1) [22], with mutations in the 
CYP24A1 gene being associated with dysregulated catabo-
lism of 1,25-(OH)2D3 [23].
Active 1,25-(OH)2D3 has an established role in regulat-
ing bone metabolism and calcium homeostasis, but it has 
also been shown to modulate key mechanisms in innate and 
adaptive immunity [24–26] (Fig. 1). The nuclear receptor for 
1,25-(OH)2D3 (the vitamin D receptor (VDR)) is expressed 
by a plethora of immune cells, including monocytes/mac-
rophage, dendritic cells (DC), neutrophils and B and T 
cells [27, 28]. This, coupled with the capacity for localised 
CYP27B1-mediated synthesis of 1,25-(OH)2D3 by mono-
cytes, macrophages and DC [13, 14], supports a role for 
vitamin D as an important contributor to normal immune 
function. The remainder of the review will focus on this 
activity of vitamin D and the impact that this may have on 
the chronic inflammatory/autoimmune disease RA.
Vitamin D and Immunity
The multi-modal innate immune system is the body’s first 
line of defence against pathogens, comprising physical bar-
riers (e.g. epithelium), chemical barriers (e.g. stomach acid), 
complement proteins and cellular responses such as those 
mediated by macrophage, DC and neutrophils. Vitamin 
D participates in several of these processes, including the 
maintenance of barrier function in the intestine, by regulat-
ing tight junctions [29] and intestinal epithelial cell apopto-
sis [30]. However, to date, studies of vitamin D and innate 
immunity have predominantly explored its impact on anti-
gen-presenting cells, such as macrophages and DC, which 
participate in the recognition of and response to pathogen-
associated molecular patterns (PAMPs) via pattern recog-
nition receptors (PRR) [25, 26] (see Fig. 1). DNA target 
sequences for 1,25-(OH)2D3-bound to VDR, referred to as 
vitamin D response elements (VDRE) have been found in 
multiple genes associated with PRR responses, including 
the antibacterial proteins NOD2 [31], hepcidin antimicrobial 
protein (HAMP) [32], cathelicidin (CAMP) [33], B-defensin 
2 (DEFB4) [33, 34] and TREM-1 [35]. Toll-Like Receptors 
(TLRs) are an important group of PRR, and 1,25-(OH)2D3 
has been shown to downregulate TLR2 and TLR4 in mono-
cytes [36], abrogating over-elaboration of TLR immune 
responses to PAMPs and damage-associated molecular pat-
terns (DAMPs). In a separate study, methylation of the Vita-
min D Receptor (VDR) gene and single-nucleotide polymor-
phisms in the VDR were also found to alter VDR-mediated 
TLR1/2 signalling in monocytes [37].
Vitamin D is also known to differentially regulate innate 
immune cell subsets, influencing cell maturation, metabo-
lism and antigen presentation, alongside response to and 
production of cytokines and chemokines [13, 14, 38, 39]. 
Notably, mature DC express CYP27B1 but little VDR, 
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whereas the converse is true for immature DC [13]. This 
has led to the hypothesis that mature DC may in fact pro-
duce vitamin D locally on activation, which then acts on 
immature DC to modulate immune responses [13, 40]. The 
principal effect of 1,25-(OH)2D3 on DC is to suppress matu-
ration markers such as CD80/CD86 [41–43] and CD83 [44], 
increase IL-10 production and decrease pro-inflammatory 
cytokines [41, 45, 46]. In this way, 1,25(OH)2D3 promotes 
an immature, tolerogenic DC phenotype [47–49], thereby 
reducing antigen presentation to T cells.
Adaptive immune cells are also modulated directly by 
1,25-(OH)2D3, with VDR being transiently expressed by 
developing thymocytes, and re-activation of VDR expres-
sion in peripheral T and B cells following immune challenge 
[50, 51]. 1,25-(OH)2D3 was initially thought to act pri-
marily as a regulator of T and B cell proliferation, but is 
now known to play a more important role in regulating T 
cell phenotype [24, 52–54]. In particular, 1,25-(OH)2D3 
has been shown to suppress inflammatory interleukin-17 
expressing CD4+ T-helper (Th) cells (Th17) [55] and Th1 
cells [56], whilst promoting differentiation of Th2 cells [57] 
and regulatory T cells (Treg) [58, 59] (see Fig. 1). However, 
vitamin D may also promote some immune responses by 
enhancing effector T cell responses including CD8+ cyto-
toxic function [53], and other studies have reported a role for 
1,25-(OH)2D3 in promoting T cell receptor (TCR) expres-
sion and T cell activation [60]. Although less well studied, 
1,25-(OH)2D3 has also been shown to modulate the function 
Fig. 1  Role of vitamin D in the immune system. Schematic represen-
tation of cells from the innate and adaptive immune systems. Mono-
cyte/macrophages from the innate immune system expression pattern 
recognition receptors (PRR) such as toll-like receptors (TLR), and 
response to pathogen-associated molecular patterns (PAMPs) such 
as lipopolysaccharide (LPS). PAMP–PRR responses include induc-
tion of transcription to increased expression of the vitamin D recep-
tor (VDR) and the vitamin D-activating enzyme 1α-hydroxylase 
(CYP27B1) via STAT 1 or 5, AP-1, NF-κB or CEBP response ele-
ments. This increases monocyte/macrophage capacity to metabolise 
25-hydroxyvitamin D3 (25-OHD3) to 1,25-dihydroxyvitamin D3 
(1,25-(OH)2D3), which then interacts with VDR to regulate gene 
expression via DNA vitamin D response elements (VDRE). Promi-
nent target genes for regulation by 1,25-(OH)2D3 include Nucleo-
tide-binding oligomerization domain-containing protein 2 (NOD2), 
hepcidin antimicrobial protein (HAMP), cathelicidin (CAMP) and 
β-defensin 2 (DEFB4). 1,25-(OH)2D3 also enhances pathogen kill-
ing by inducing autophagy and reactive oxygen species (ROS), but 
acts to inhibit inflammation by suppressing inflammatory cytokines 
and expression of TLR2/4. Monocytes/macrophages may contribute 
to local levels of 1,25-(OH)2D3 which may then act on non-immune 
cells such as local tissue fibroblasts, chondrocytes or epithelial cells. 
For other innate immunity cells such as dendritic cells (DC), dif-
ferentiation of these cells from immature (iDC) to mature (mDC) 
phenotypes is associated with increased expression of CYP27B1 
but decreased expression of VDR, suggesting local conversion of 
25-OHD3 to 1,25-(OH)2D3, which results in a paracrine effect to 
generate tolerogenic DC. Synthesis of 1,25-(OH)2D3 by mDC may 
also have paracrine effects on cells from the adaptive immune system 
such as T cells which, when activated, express VDR and respond to 
1,25-(OH)2D3 by inducing Th2 and Treg phenotypes whilst suppress-
ing Th1 and Th17 inflammatory phenotypes. 1,25-(OH)2D3 can also 
act on B cells to decrease CD40 expression and enhance class switch-
ing
 S. R. Harrison et al.
1 3
of other cytotoxic lymphocytes such as natural killer cells 
(NK), with apparent effects of NK cell activation [61]. Like-
wise, effects of vitamin D have been described for natural 
killer T cells (NKT), and NKT cell development is lost in 
mice lacking the VDR gene [62]. In contrast to the wide 
range of data on vitamin D and T cells, there is a scarcity 
of detailed studies for effects of 1,25-(OH)2D3 on B cells, 
which may include indirect effects via T cell modulation 
[63], and direct B cell effects on class switching [64], IL-10 
production [65] and CCR10 production [66].
Vitamin D in Autoimmune Disease
Given the proposed role for vitamin D as an immune regula-
tor, it is perhaps unsurprising that vitamin D deficiency has 
been linked to both allergic [67] and autoimmune diseases 
[4–8, 68, 69]. The increasing incidence/prevalence of MS 
proportional to distance from the equator, suggests that envi-
ronmental factors such as sunlight and vitamin D may be 
involved in disease aetiology [70]. This is further underlined 
by studies from the UK showing that risk of immune-related 
diseases is significantly influenced by the season of birth as 
the serum 25-OHD3 levels is associated with this [71]. Like-
wise, genetic variants associated with heritable effects on 
vitamin D status have also been linked to MS disease onset 
and progression [72, 73]. However, differences between 
genders [74], ethnic groups [75] and potentially different 
subtypes of MS [76], make it difficult to decipher the exact 
role of vitamin D in MS. Furthermore, although vitamin D 
supplementation has been successful in ameliorating MS 
symptoms in some studies [77–80], this has not been dem-
onstrated consistently [81]. Larger randomised controlled 
trials (RCTs) are now needed to establish whether vitamin D 
supplementation can reduce risk, severity and/or progression 
of MS. Similar to MS, vitamin D deficiency is also prevalent 
in SLE [82], where low serum vitamin D has been associated 
with dysregulation of autophagy [83], increased circulating 
levels of IFNα [84], increased CD4+/CD8+ T cells and a 
reduction in pro-inflammatory cytokines [85]. Vitamin D 
intake has been shown to have variable impact on SLE, with 
some studies showing no effect on disease severity [86–88] 
whilst another study reported decreased disease activity in 
young adults with SLE [89]. As with MS, more research is 
needed to fully define optimal doses and timing of interven-
tion for vitamin D supplementation.
T1D is another autoimmune disease with reported links 
to vitamin D status, with vitamin D deficiency correlating 
with T1D risk severity [90, 91]. A prospective, non-blinded 
non-randomised controlled trial has also shown that T1D 
patients supplemented with vitamin D and with higher 
serum 25-OHD3 are more likely to have improved glycemic 
control [92]. T1D has also been linked to single-nucleotide 
polymorphic variants in the CYP27B1 [93–95] and VDR [96, 
97] genes. In vivo treatment with the active form of vitamin 
D, 1,25-(OH)2D3, was shown to completely suppress T1D 
disease in the NOD experimental mouse [98]. In humans, 
clinical trials involving supplementation with vitamin D3 
or the precursor molecule 1α-hydroxyvitamin D3 in T1D 
patients have produced mixed results; some studies have 
reported delay of β-cell destruction in supplemented trial 
groups compared to non-supplemented groups [99–101], 
whilst others found no significant improvements of on β-cell 
preservation [102, 103].
Vitamin D deficiency has also being linked to autoim-
mune gastrointestinal disorders such as Crohn’s disease, 
a major form of IBD [104–107]. The role of vitamin D 
as a regulator of immune function in IBD has also been 
studied in vivo in mouse models. Knockout of the mouse 
genes for VDR (Vdr) [108] or 1α-hydroxylase (Cyp27b1) 
[109] shows increased severity of artificially induced coli-
tis similar to IBD. Other studies have shown that vitamin 
D-deficient mice have increased severity of induced coli-
tis, with this effect being linked to aberrant innate immune 
responses within the gastrointestinal tract [110]. Further-
more, it has been shown that the VDR, in conjunction with 
1,25-(OH)2D3, protects against the onset of colitis in mice 
by maintaining barrier function within the gastrointestinal 
mucosal epithelium [111]. Despite these positive studies, 
it is still unclear whether vitamin D deficiency is a direct 
cause of IBD including Crohn’s disease, or whether there is 
a reverse causation effect.
Vitamin D and Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory/auto-
immune arthritis characterised by synovitis of peripheral 
joints, with extra-articular manifestations. If untreated, 
unopposed inflammation leads to joint destruction, loss of 
function and disability, and RA is also associated with pre-
mature mortality secondary, at least in part, to the effects of 
chronic inflammation on cardiovascular health [112]. Like 
other autoimmune diseases, there is growing interest in the 
role of vitamin D deficiency in the aetiopathogenesis of RA 
[9]. RA is thought to be triggered by environmental factors 
[113], in patients with an underlying genetic susceptibility 
[114, 115] leading to dysfunction of innate and adaptive 
immunity, tipping the balance in preference of autoimmun-
ity over tolerance [116]. Whilst smoking is well recognised 
as a strong environmental risk factor other potential factors 
include vitamin D [9].
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Vitamin D Status and RA Disease Risk and Progress
In a recent meta-analysis and systematic review, Lin J et al. 
analysed 24 studies published prior to May 2015 whose 
focus was the relationship between serum 25-OHD3 and 
clinical/laboratory indices of RA disease activity. Over-
all, they reported an inverse relationship between serum 
25-OHD3 and RA disease activity [117]. However, they 
also identified important differences between patient sub-
groups, including a stronger inverse relationship between 
RA disease activity and serum 25-OHD3 in studies from 
developing countries, and in low-latitude climates. Since 
the publication of this meta-analysis, further studies have 
been conducted. Therefore, to establish a clearer picture 
of whether vitamin D levels are indeed significantly lower 
in RA, and are linked to disease activity, all studies of 
vitamin D levels in RA patients currently listed on Pub-
med are summarised in Table 1. The search terms “vita-
min D levels” and “rheumatoid arthritis” were used, and 
no restrictions on study date were applied. In addition, 
studies included in the meta-analysis (referenced above) 
were also included. The collected studies listed in Table 1 
underline the significant heterogeneity between studies and 
their findings, making it difficult to determine a clear role 
for vitamin D deficiency in the onset, progression and/
or severity of RA. Studies to date have been conducted 
in over 20 countries, which invariably means that there 
will be confounding differences in environmental factors 
including sunlight exposure and diet, and genetic factors. 
Moreover, the overwhelming majority of the reported 
studies were observational or cross-sectional by design, 
and as such can only report on the association between RA 
disease and vitamin D, rather than a causal role.
RA is a heterogeneous disease, yet few studies have con-
sidered analysing RA subgroups based on antibody status, 
disease severity or duration. Where subgroups have been 
defined, this is often based on disease activity score 28 
(DAS-28); a composite score that captures different sub-
jective and objective measures of disease activity, hence 
the potential for skewing of results by one component. One 
study that did address this reported no correlation between 
vitamin D levels and DAS-28, with or without the inclusion 
of the patient global visual analogue scale score (Patient 
global VAS)—a scale for evaluating the patient’s overall 
perception of their RA activity. However, patient global 
VAS on its own did correlate with serum vitamin D lev-
els [118]. In 2015, Cooles et al. reported data showing the 
relationship between serum 25-OHD3 levels and various 
clinical parameters in early RA (median symptom duration 
12 weeks, range 4–104 weeks) [119]. They found no clear 
association between 25-OHD3 and early RA, but in early 
osteoarthritis (OA) 25-OHD3 was inversely associated with 
global health visual analogue scale scores (GH-VAS). This 
suggests that OA, which commonly co-exists with RA, may 
act as a confounder in interpreting the relationship between 
vitamin D and RA. These observations are intriguing, and 
need to be further explored to determine the role, if any, for 
vitamin D in pain and fatigue associated with RA.
Relatively few studies have assessed the impact of 
RA treatment regimens on the apparent inverse correla-
tion between serum 25-OHD3 and RA disease activity 
[120–122]. Treatment for RA is aimed at reducing disease 
activity, and therefore comparing serum 25-OHD3 levels 
with measures of disease activity after the initiation of 
treatment could mask prior effects of vitamin D deficiency 
on treatment naïve disease. Since the 1990s, an early and 
aggressive approach to the management of new RA has been 
widely used in order to maximise chances of inducing remis-
sion [123]. Today, this strategy is fully integrated in clinical 
practice, but its application in the context of low vitamin 
D, and vitamin D replacement, for treatment naive, newly 
diagnosed RA patients, is still unclear.
As well as clinical and biochemical differences in sub-
groups of RA, there are also likely genetic differences which 
may influence the relative importance of vitamin D in the 
immunopathogenesis of disease. For example, Dennis et al. 
identified four distinct synovial tissue gene expression pro-
files in a cohort of RA patients [124]. Although some of 
these differences in gene expression may be related to the 
patient’s disease duration or treatment regimen, it seems 
unlikely that this sufficiently explains all the observed dif-
ferences, and that distinctly different gene signatures may 
indeed characterise different subsets of RA. Accordingly, it 
seems plausible that vitamin D deficiency may play slightly 
different roles in the aetiopathogenesis and progression of 
disease in different groups of patients. Ultimately, the role of 
vitamin D in RA appears far too complex to be understood 
through simple observational methods.
To date, studies of RA disease and vitamin D have 
focused on the link between RA and serum levels of the 
main circulating form of vitamin D, 25-OHD3. However, 
25OHD3 is an inactive precursor for 1,25-(OH)2D3 and 
therefore has limited functional relevance for immunomodu-
lation. Consequently, there has been a revival of interest in 
the role of other vitamin D metabolites both in serum and 
disease-affected synovial fluid as potentially more informa-
tive markers for vitamin D function in RA. Research on this 
subject began more than 25 years ago with seminal studies 
of vitamin D metabolism in RA tissues [125–127]. These 
reports indicated that concentrations of 25-OHD3 were sig-
nificantly lower in synovial fluid relative to paired patient 
blood, but also revealed significant capacity for the genera-
tion of 1,25-(OH)2D3 by macrophages isolated from syno-
vial fluid [127]. In more recent studies, we have measured 
multiple vitamin D metabolites—the vitamin D ‘metabo-
lome’ in paired serum and synovial fluid from patients 
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with established RA, reactive arthritis and healthy controls 
using the current gold standard for vitamin D analysis, liq-
uid chromatography–tandem mass spectrometry (LC–MS/
MS) [128]. These studies showed that for markers such as 
swollen joint count (SJC), synovial fluid levels of vitamin D 
metabolites correlated better with RA disease activity than 
their circulating serum counterparts [128].
Another area of contention for vitamin D and RA con-
cerns the definition of vitamin D deficiency itself (Table 1). 
In the UK, the National Institute of Clinical Excellence 
(NICE) recommends diagnosis of vitamin D deficiency 
when serum 25-OHD3 is < 30 ng/mL, and states that for 
some people 30-50 ng/mL may be insufficient, citing recom-
mendations from the national osteoporosis society guide-
lines [129, 130]. Hence, there appears to be an ambiguity 
around whether or not some patients need more vitamin D 
than others. Current NICE guidance does not define what 
constitutes adequate vitamin D status in patients of dif-
ferent ages, sex, ethnicities or disease states; for example, 
patients at risk of RA vs patients with established RA, or 
in other inflammatory diseases. To date, few studies have 
attempted to define what adequate supplementation means 
in RA. A cohort study published in 2012 observed that even 
supplementation 800-880 IU/day did not achieve adequate 
repletion of vitamin D (defined as > 20 ng/mL) in 27.7% of 
RA patients who were vitamin D-deficient, although dura-
tion of therapy was not reported [131]. This suggests that 
different levels of vitamin D replacement may be required 
in different RA patients, depending on pre-supplementa-
tion of vitamin D levels, sunlight exposure and skin col-
our (darker skin absorbs less UV light to make vitamin 
D). Failure to adequately replete RA patients could also be 
related to poor treatment compliance or inadequate dura-
tion of supplementation. Importantly, inadequate repletion 
was related to higher HAQ scores for RA patients, implying 
that inadequate improvement of vitamin D status following 
supplementation had poorer outcomes [131]. Alternatively 
higher disease activity may simply be associated with less 
time spent outdoors, indirectly impacting sunlight exposure 
and skin synthesis of vitamin D. Further RCTs are needed 
to more clearly define the optimal levels of vitamin D for 
patients with RA, and how to achieve and maintain these 
levels. The next section of the review describes the reported 
supplementation trials for vitamin D and RA.
Vitamin D Supplementation Trials in RA
Ultimately, defining vitamin D deficiency in the context 
of RA is of clinical interest only if replacing vitamin D in 
RA patients who are deficient is likely to improve disease 
symptoms, or even prevent the onset of RA in those at risk. 
To date, vitamin D supplementation trials for RA have var-
ied appreciably in terms of patient numbers, characteristics, 
disease duration and severity, concomitant medication regi-
men, type of/duration of supplementation regimen, number 
of outcomes and period over which these outcomes were 
measured (Table 2). A recent meta-analysis identified 9 
RCTs of vitamin D supplementation for ≥ 3 months in rheu-
matic diseases, including 5 studies of RA patients [132]. In 
RA, there was a decrease in the rate of disease flare, VAS 
and DAS-28 with vitamin D supplementation; however, all 
failed to reach statistical significance. Similar findings have 
also been reported in previous meta-analyses on this sub-
ject [133]. Conversely, a meta-analysis conducted in 2012 
found that all but one of the 11 studies included in the meta-
analysis suggested low vitamin D intake was linked with 
both increased risk of RA and greater disease activity [134]; 
however, the studies included in that analysis were cohort/
association by design, and not RCTs. Challenges associated 
with identifying whether vitamin D supplementation has 
a beneficial effect in RCTs to date include inter-study het-
erogeneity and relatively small sample numbers for a meta-
analysis, with only 5 RCTs included, thus emphasising the 
need for larger RCTs in different subsets of RA patients to 
fully elucidate the role, if any, for vitamin D supplementa-
tion in the management of RA. In addition, there may be 
differences in vitamin D-binding protein levels, and other 
genetic variants, which influence the efficacy of vitamin D 
supplementation [135]. Vitamin D supplementation in low/
moderate doses is not thought to be harmful to patients, 
has wider health benefits, is relatively inexpensive and has 
fewer side effects/interactions compared with many other 
commonly used treatments for RA, such as non-steroidal 
anti-inflammatory drugs (NSAIDs), or conventional syn-
thetic or biological disease-modifying anti-rheumatic drugs 
(DMARDs). Evidence is also emerging that vitamin D may 
augment certain therapies in RA. In one in vitro study, 
vitamin D 1,25-(OH)2D3 was shown to act synergistically 
with the biologic drug abatacept to inhibit T cell activation 
driven by anti-CD3 cross-linking, and promote a pro-regu-
latory CD28 phenotype [136]. The potential for enhancing 
the effects of biologics with simple, low-risk addition of 
1,25-(OH)2D3 is interesting, and further work is required to 
validate this initial in vitro finding.
Cellular Targets for Vitamin D in RA
The pathogenesis of RA involves both innate and adaptive 
immune activities. Adaptive CD4+ T cells are critical in the 
pathogenesis of RA. For example, T cells are a source of 
RANKL, leading to osteoclast activation and subsequent 
joint destruction in RA [137]. However, antigen-presenting 
cells (APCs) such as DC also contribute to RA by providing 
the necessary co-stimulatory signals required for CD4+ T 
cell activation [138, 139]. Not only do APCs activate T 
cell proliferation, but they also influence T cell phenotype 
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(Th1/Th2/Th17/Treg) and subsequent cytokine profile, and 
Th1/17 are both known to be relevant to the pathogenesis of 
RA [140, 141]. With this in mind, it is clear that the immu-
nomodulatory activities of 1,25-(OH)2D3 described earlier 
in the review (see Fig. 1) have the potential to influence 
both the innate and adaptive immune cell types that con-
tribute to the dysregulated immunity associated with RA. 
In a murine model of RA, tolerogenic DCs (tolDCs) were 
observed to reduce severity and progression of RA disease 
by increasing IL-10-producing T cell numbers and reducing 
Th17 cell counts [142]. It is therefore interesting to note that 
1,25-(OH)2D3 can induce tolDC [143], and tolDCs, gener-
ated ex vivo using 1,25-(OH)2D3 have been proposed as 
a potential strategy for RA therapy [144]. In this instance, 
1,25-(OH)2D3 was used in combination with the glucocor-
ticoid dexamethasone which is known to promote a tolDC 
phenotype [58].
In addition to enhanced activity of Th1 and Th17 cells, 
RA disease is also characterised by reduced Treg activ-
ity, including decreased Treg numbers [145], a reduction 
in Treg: Th1/Th17 ratio [146], altered Treg function [147] 
and differences in Treg number and function in the periph-
eral blood compared with the synovium [148]. However, 
in some studies, numbers of circulating Treg in RA were 
similar to those found in healthy controls [149] and osteo-
arthritis patients [150]. Tregs are likely to be a key target for 
vitamin D in RA. In animal models of experimental autoim-
mune encephalitis (the most widely used mouse model of 
MS), IBD and T1D, 1,25-(OH)2D3 promotes a Treg pheno-
type and augment IL-10 production, thus inhibiting Th17 
responses and ameliorating disease [54]. In studies using 
human Tregs, the 1,25-(OH)2D3 analogue TX527 skewed 
the Treg cell phenotype in favour of migration to sites of 
inflammation [151], whilst also promoting a stable Treg 
phenotype [152]. The growing pool of ex vivo and in vitro 
evidence linking vitamin D and Treg function now requires 
replication in vivo, particularly in diseases such as RA.
To date, most studies of the T cell actions of 1,25-
(OH)2D3 have been based on the analysis of mixed popula-
tions of circulating T cells from healthy donors. However, 
in recent studies, we have shown that T cells from synovial 
fluid of RA patients’ inflamed joints are relatively insensitive 
to 1,25-(OH)2D3, despite expressing the VDR machinery 
required for 1,25-(OH)2D3 signalling [153]. This is due, in 
part, to decreased 1,25-(OH)2D3 responsiveness in the mem-
ory T cells that predominate in RA synovial fluid, but also 
involves tissue-specific effects, with synovial fluid memory 
T cells showing decreased responses to 1,25-(OH)2D3 rela-
tive to peripheral blood memory T cells [153]. Based on 
these observations, we have proposed that immunomodula-
tory responses to vitamin D at tissue sites of inflammation 
are impaired by target cell insensitivity to 1,25-(OH)2D3. If 
this is the case, then conventional analysis of the effects of 
vitamin D using circulating blood immune cells can only 
provide a limited picture of immunomodulation by vitamin 
D in diseases such as RA. Likewise, to overcome the vitamin 
D-insensitivity observed in RA patient, inflamed joints may 
require alternative strategies. This could include the use of 
higher doses of vitamin D supplements to enhance localised 
tissue levels of 1,25-(OH)2D3, or the use of vitamin D as an 
adjunct to other RA therapies. With respect to the latter, we 
have recently shown that 1,25-(OH)2D3 can more potently 
inhibit T cell activation when used in combination with the 
CD28 co-stimulatory blocker abatacept [154].
Beyond the actions of innate and adaptive immune cells, 
synovial fibroblasts (synoviocytes) also play an impor-
tant role in the pathogenesis of RA. In studies using the 
immortalised synoviocyte cell line, MH7A, 1,25-(OH)2D3 
has been shown to promote synoviocyte apoptosis, which 
might protect against RA, but only when cells were treated 
with both tumor necrosis factor α (TNFα) and 1,25-(OH)2D3 
[155]. These observations suggest that TNFα is required for 
1,25-(OH)2D3 to have anti-inflammatory effects in RA, 
which is a paradoxical observation given the use of TNFα 
inhibitors as biological treatment in RA. Conversely, other 
studies have reported synergistic effects of TNFα inhibition 
and 1,25-(OH)2D3 in suppressing Th17-mediated inflam-
mation [156], suggesting a complex interaction between 
TNFα and 1,25-(OH)2D3. Other studies using MH7A cells 
have shown synergistic effects of interleukin 1β (IL-1β) and 
1,25-(OH)2D3 in suppressing the production of IL-6 and 
TNFβ levels, and Th17-inducing cytokines (IL-1β, IL-6 
and IL-23) synergistically enhanced the pro-regulatory 
effect of 1,25-(OH)2D3 on T cell phenotype [136], further 
emphasising important interactions between 1,25-(OH)2D3 
and pro-inflammatory cytokines in RA [157]. Collectively, 
these observations suggest that the beneficial effects of 1,25-
(OH)2D3 are most potent when the threshold for activation 
of the immune response is breached, leading to concomitant 
production of inflammatory cytokines. Therefore, in the set-
ting of inflammation, vitamin D appears to function as a 
negative-feedback regulator, attenuating the inflammatory 
immune responses. Vitamin D may also influence the syno-
vial microenvironment by modulating factors that influence 
joint bone and cartilage damage. In studies using synovio-
cytes and articular chondrocytes from RA patients, 1,25-
(OH)2D3 was shown to regulate matric metalloproteinases 
and prostaglandins, but only in the presence of IL-1β [158], 
suggesting, as outlined earlier, that 1,25-(OH)2D3 is only 
effective as a regulator of synoviocytes in the setting of RA 
disease inflammation.
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Conclusions
Future studies of vitamin D and RA are needed firstly to 
expand our current understanding of the mechanisms by 
which 1,25-(OH)2D3 is able to regulate key cells associ-
ated with RA. In particular, the observation that T cells 
from the inflamed joints of RA patients are insensitive to 
1,25-(OH)2D3 [153] indicates that RA disease is associ-
ated with a corruption of vitamin D signalling that may be 
fundamentally important for RA disease pathology, and the 
therapeutic use of vitamin D. A key question that remains 
to be answered is whether vitamin D has greater benefits in 
protecting against the onset of RA as opposed to its potential 
application as a therapy for established RA disease. Thus, 
future studies to assess the effects of vitamin D supplemen-
tation on disease prevention in individuals at risk of RA, 
and disease development in those at early stages of RA, are 
required. These studies are likely to be informed by recent 
meta-analyses for immune effects of vitamin D. Notably, the 
observation from the analysis of acute respiratory infection 
trials that vitamin D supplementation was more beneficial in 
patients with low baseline serum vitamin D, and was more 
effective when supplementation was used as lower daily or 
weekly dosing [159], provides some important pointers for 
future studies of vitamin D and RA. Repeated lower doses of 
vitamin D supplementation would also help to avoid poten-
tial adverse effects of higher doses of vitamin D, in particu-
lar the reported increased risk of falls in elderly patients 
receiving a single bolus of higher-dose vitamin D [160]. 
Future studies also need to take into consideration clinical 
subgroups of patients, including distinguishing between 
ethnic groups and disease of different durations. The poten-
tial for a simple, low-risk and low-cost intervention such as 
vitamin D as a plausible adjunctive treatment for RA is an 
exciting notion. Robust evidence to support wider routine 
use of vitamin D supplementation in RA has the potential 
to significantly enhance treatment for RA and other autoim-
mune diseases.
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